Study Links SSRIs To Increased Risk Of Hemorrhagic Stroke
Study Links SSRIs To Increased Risk Of Hemorrhagic Stroke
Introduction
On August 31, Massachusetts General Hospital researchers published a single-center observational cohort study in the medical journal JAMA Neurology, indicating that selective serotonin reuptake inhibitor (SSRI) antidepressants, prescribed to individuals after suffering a stroke, may increase the risk of suffering a brain bleed later.
The intracerebral hemorrhage (ICH) study involved 1,200 adults who were hospitalized, treated, and discharged after suffering from a stroke. The ICH survivors had depression from January 2006 to December 2017 and were followed for 54 months.
SSRIs, such as Paxil or Zoloft, are widely used to treat depression after a stroke caused by brain bleeds. According to the study, the increased risk of ICH recurrence or having another brain bleed was more for patients with preexisting clinical, genetic, or neuroimaging risk factors for hemorrhagic stroke. The patients were 71 years old, on average, and the risk heightened in people who consumed SSRI antidepressants as compared to the ones who didn't, as per the report.
In a study published in 2016, SSRI antidepressants were linked to a higher risk of recurring brain bleeds among patients taking blood thinners like Warfarin or Xarelto.
The researchers concluded that although SSRIs are considered the primary treatment after stroke, it may not be the best course of treatment for patients who have a higher risk of brain bleeds after stroke and may lead to another hemorrhagic bleed in the brain. The researchers also warned doctors to weigh the decision to treat depression among stroke survivors with SSRIs against the increased risk of the patient suffering another brain bleed.
Latest News
Study Links Roundup Chemical to Long-Term Brain Damage
A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…